DOM FIGURE 1 Effect of single exposure to AZD1656 or PF-04991532 on blood glucose and insulin and liver gene expression.

Male C57BL/6 mice were treated with vehicle or AZD1656 (A,E) at the doses indicated 2h before an oral glucose tolerance test or with PF-04991532 (B,F) 1h before the oral glucose tolerance test. C,G. Changes in blood glucose (C) and insulin (G) after treatment with AZD1656 or PF-04991532 before glucose gavage. D. Blood glucose, area under the curve. H. Plasma insulin, area under the curve. I. Liver mRNA levels for the indicated genes normalized to TATA-Binding Protein (TBP) and to vehicle controls. Means ± SEM, n=8, * P < 0.05 relative to vehicle, except for C,G relative to time zero.

将雄性C57BL/6小鼠分为赋形剂对照组与AZD1656给药组（对应图版A、E），于口服葡萄糖耐量试验前2小时给药；另设置PF-04991532给药组（对应图版B、F），于口服葡萄糖耐量试验前1小时给药。
图版C、G展示了葡萄糖灌胃前经AZD1656或PF-04991532处理后，血糖（对应图C）与胰岛素（对应图G）的动态变化情况。
图版D：血糖水平的曲线下面积。
图版H：血浆胰岛素水平的曲线下面积。
图版I：以TATA盒结合蛋白（TATA-Binding Protein, TBP）与赋形剂对照组为参照进行归一化后，目标基因的肝脏mRNA表达水平。
所有数据以均值±标准误（Standard Error of the Mean, SEM）表示，每组样本量n=8；除图版C、G为与时间零点比较外，其余组别均与赋形剂对照组比较，*P<0.05为具有统计学显著性差异。